Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus LOPRESSIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus LOPRESSIDONE.
DEMI-REGROTON vs LOPRESSIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Lopressidone is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2, and also blocks alpha1-adrenergic and H1 histamine receptors.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
Oral: 5 mg twice daily, titrate as tolerated up to 20 mg twice daily. Maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
12-15 hours; allows once-daily dosing, but steady-state reached in ~3-5 days.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal: ~60% (as unchanged drug); Fecal: ~30% (as metabolites); Biliary: minor (<5%).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination